REVIVA PHARMACEUTICALS HOLDINGS, INC.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2020 - Q4(Sep 20 · Oct 20 · Nov 20)
Total Assets
$16M
↑+2.7% +$420Kvs FY2024
Total Liabilities
$7M
↓-50.2% -$7Mvs FY2024
Equity
$9M
↑+964.2% +$8Mvs FY2024
Cash
$14M
↑+7.1% +$962Kvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $16M | $16M |
| Current Assets | $15M | $15M |
| Cash | $14M | $13M |
| ST Investments | $0 | $0 |
| Receivables | $0 | $0 |
| Inventory | $0 | $0 |
| Other Current | $665K | $1M |
| Non-Current Assets | $820K | $820K |
| PPE | $0 | $0 |
| Goodwill | $0 | $0 |
| Intangibles | $0 | $0 |
| Investments | $0 | $0 |
| Other Non-Current | $820K | $820K |
| Total Liab+Eq | $16M | $16M |
| Current Liab. | $7M | $15M |
| Accounts Payable | $3M | $6M |
| Short-Term Debt | $407K | $458K |
| Deferred Revenue | $0 | $0 |
| Other CL | $4M | $8M |
| Non-Current Liab. | $0 | $89K |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $0 | $89K |
| Equity | $9M | $813K |
| Retained Earnings | $184M | $164M |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · RVPH · Comparing FY2025 vs FY2024